Clinical • Trial completion • Enrollment change • Trial completion date • Combination therapy
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • MAGEA3 (MAGE Family Member A3)
|
EGFR mutation • ALK translocation
|
Keytruda (pembrolizumab) • Marabex (MAGE-A3 vaccine)